Do you have to stay on Mounjaro for life?

Does the Mounjaro licence set a time limit on treatment?

The UK marketing authorisation for tirzepatide does not place a cap on how long adults can use it for weight management. That puts it in a different position from semaglutide (Wegovy), where NICE's appraisal of semaglutide for weight management (TA875) recommends a maximum of two years of NHS treatment within specialist services, a restriction tied to that specific funding decision, not to any biological argument that two years is always enough. Mounjaro carries no equivalent time ceiling. The NHS tirzepatide patient information page reinforces that treatment should continue as long as it is working and clinically appropriate, with any changes discussed with a doctor or pharmacist. If you reach the highest dose you tolerate and lose less than 5% of your body weight after six months, NICE's guidance (TA1026) suggests that a prescriber should review whether continuing is worthwhile. That is a progress check, not an automatic stop. For most people who do respond well, nothing in the current guidance rules out staying on Mounjaro beyond a year, beyond two years, or indefinitely, and if you want to explore what that really means in practice, our dedicated page on Mounjaro for life looks at the topic in full, provided a clinician continues to oversee it and the benefit justifies ongoing treatment.

What actually happens to weight when people stop?

This is probably the question behind your question, and it deserves a straight answer. In the SURMOUNT-4 trial (a study specifically designed to examine what happens after stopping tirzepatide) participants who had lost around 20% of their body weight over a year of treatment then either continued or switched to placebo. Those who stopped regained most of the weight within the following year; those who continued maintained their loss and lost a little more. The biology behind this is well understood: tirzepatide works by activating the GIP and GLP-1 receptors that regulate hunger and satiety. Stop the medicine and those pathways return to their pre-treatment state. That is not a design flaw, it reflects the fact that obesity involves persistent hormonal and metabolic changes, not a temporary imbalance. If you are weighing up the long-term picture, our tirzepatide overview page explains the mechanism in more detail. The honest framing is that for many people Mounjaro is more like a blood-pressure tablet than a short course of antibiotics, and if you are asking whether you can take Mounjaro for life, that page sets out what the evidence currently says about sustained, open-ended use.

Is indefinite use safe, and what does ongoing treatment look like?

If you have been wondering about this, you are not alone. The idea of taking any medicine long-term raises reasonable questions, and it is worth sitting with them rather than dismissing them. What the clinical data currently show is reassuring: the safety profile of tirzepatide over 72-week trials in thousands of adults was consistent, with no new signals emerging over time at the doses studied. Side effects (mostly gastrointestinal and most noticeable in the early weeks) did not worsen with prolonged use. Longer-term data are still accumulating, as they always are for newer medicines; Mounjaro carries a Black Triangle (▼) designation, meaning the MHRA actively collects additional information, which is a normal feature for recently approved treatments. In practice, ongoing treatment through a registered service like nume means your case is clinically reviewed before every repeat order, not just at the start. A prescriber checks your progress, assesses any changes in your health, and confirms that continuing is appropriate. That structure matters: a medicine taken without review is a different proposition from supervised long-term care. If cost over the long term is part of your thinking, it is worth reading what transparent private pricing actually covers, our guide to Mounjaro costs in the UK breaks down what legitimate treatment includes.

How do prescribers approach the stopping decision in practice?

There is no single rule. Prescribers look at several things: how much weight has been lost, how well it has been maintained, what the original health risks were, whether weight-related conditions (high blood pressure, type 2 diabetes, sleep apnoea) have improved, and what the patient's own goals and preferences are. Some people reach a stable, healthy weight and choose to stop with a clear plan for diet and activity. Some find that reducing to a lower maintenance dose preserves most of the benefit with a lighter treatment burden, dose reduction is an area of active clinical interest, though it is not yet part of the licensed titration schedule and would be an individual clinical decision. Others decide the ongoing health benefit justifies staying on treatment long-term, and our page exploring whether you can be on Mounjaro for life covers the clinical and practical factors that tend to shape that decision. None of these is the wrong answer in principle; all of them require a conversation rather than a self-directed choice. Our page on long-term Mounjaro use explores what that conversation typically covers. The question of whether you need to stay on it for life is one a prescriber can help you think through, with your specific health picture in front of them. Speak to our prescribers through a free consultation if you would like a clinical view on your situation.